What is the recommended treatment for LGI1 encephalitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of LGI1 Encephalitis

Start high-dose corticosteroids immediately once infection is ruled out, as LGI1 encephalitis is particularly steroid-responsive, and early treatment is critical to prevent long-term cognitive impairment. 1

First-Line Acute Immunotherapy

Initial Treatment Selection

Corticosteroids are the preferred first-line agent for LGI1 encephalitis based on guideline recommendations specifically identifying this condition as steroid-responsive 1. Evidence from a 2022 Mayo Clinic study of 118 patients demonstrated that corticosteroids were significantly more effective than IVIG alone, achieving:

  • 61% resolution of faciobrachial dystonic seizures (vs 7% with IVIG, p=0.002)
  • Greater improvement in modified Rankin Scale scores (ΔmRS 2 vs 0, p=0.008)
  • Better cognitive outcomes (ΔKokmen STMS 5 points vs 0, p=0.01) 2

Treatment protocol:

  • High-dose intravenous methylprednisolone (typically 1g daily for 3-5 days)
  • Followed by oral prednisone taper over ≥3 months 3
  • Alternative first-line options if steroids contraindicated: IVIG or plasma exchange 1

When to Escalate or Combine Therapy

If no clinical, radiological, or electrophysiological improvement occurs by the end of the initial treatment cycle:

  • Add IVIG or plasma exchange to corticosteroids 1
  • Consider IVIG first in agitated patients or those with bleeding disorders
  • Consider plasma exchange first if severe hyponatremia, high thromboembolic risk, or associated demyelination 1

Important caveat: Many patients have ongoing subclinical symptoms even after apparent initial improvement. A 2024 Spanish prospective study found that 79% of patients had disrupted sleep structure and 63% had ongoing clinical features at median 88 days post-immunotherapy that were initially unrecognized but responded to additional treatment 4.

Second-Line Immunotherapy

Indications for Second-Line Agents

If no meaningful clinical or radiological response occurs 2-4 weeks after completion of combined first-line therapy, initiate second-line agents 1.

Rituximab is the preferred second-line agent for LGI1 encephalitis as this is antibody-mediated autoimmunity 1. Key evidence:

  • A 2024 prospective study found that absence of rituximab use before initial follow-up was associated with persistent cognitive deficits (OR 4.0,95% CI 1.5-10.7, p=0.0015) 4
  • A 2021 Mayo Clinic study showed that long-term steroid-sparing immunotherapy (including rituximab) reduced relapse risk (HR 0.28,95% CI 0.11-0.73, p=0.009) 5

Maintenance Immunotherapy

The evidence regarding maintenance therapy is mixed but favors long-term immunosuppression in most cases:

Arguments for maintenance therapy:

  • Relapses occur in 33-41% of patients 3, 5
  • A 2024 study showed mycophenolate mofetil significantly reduced relapse risk (HR 0.463, p=0.030) 6
  • Long-term steroid-sparing agents associated with lower relapse rates 5

Arguments for prolonged corticosteroids without maintenance:

  • A 2023 Canadian study using prolonged corticosteroids (median 6.3 months) without steroid-sparing maintenance showed 89% favorable outcomes with only 33% relapse rate 3
  • However, relapses were more common in refractory disease cases 3

Recommended approach:

  • Start bridging therapy with gradual oral prednisone taper (≥3 months) 1, 3
  • Consider rituximab or mycophenolate mofetil for maintenance in patients with:
    • Cognitive impairment at presentation (higher relapse risk, HR 3.391, p=0.043) 6
    • Persistent LGI1 antibodies in serum at follow-up 4
    • REM sleep without atonia on polysomnography 4
    • Female sex or younger age (associated with chronic epilepsy development) 5

Critical Pitfalls to Avoid

  1. Don't wait for antibody results to start treatment - begin immunotherapy once infection is excluded 7

  2. Don't assume good functional recovery means complete resolution - 65% of patients have persistent cognitive deficits at 12 months despite good mRS scores 4, and 37% have short-term memory impairments at long-term follow-up 2

  3. Don't miss faciobrachial dystonic seizures - these were unnoticed in 17% of patients but are highly steroid-responsive 4

  4. Don't undertreat early - cognitive deficits are linked to immunotherapy-resistant white matter network changes 8, suggesting a window for preventing permanent damage

  5. Screen for malignancy - perform CT chest/abdomen/pelvis as LGI1 can be paraneoplastic 1

Monitoring and Follow-up

  • Serial antibody levels in serum (and CSF if available) can guide treatment weaning 7
  • Consider videopolysomnography to detect subclinical disease activity 4
  • Neuropsychological testing to assess for persistent cognitive deficits 2
  • Monitor for relapses, particularly in first 7.5 months 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.